{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T23:57:40Z","timestamp":1774396660757,"version":"3.50.1"},"reference-count":85,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T00:00:00Z","timestamp":1701216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Strategic Research Initiative funds, Indiana University"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>As bile acids not solely play an essential role in nutrition absorption, but also in regulating metabolic functions as well as immune response, bile acids and their signaling pathways are increasingly acknowledged as potential therapeutic targets in the context of chronic liver diseases. Bile acid receptors such as G protein bile acid-activated receptor 1 and farnesoid X receptor are expressed in different immune cells engaged in innate immunity. Recently, a series of studies have revealed distinct functions of bile acids and bile acid receptors within the adaptive immune system. In addition, a variety of molecules targeting bile acid receptors and transporters are currently in advanced stages of clinical development. Autoimmune liver diseases including conditions like primary biliary cholangitis, primary sclerosing cholangitis, and autoimmune hepatitis can lead to chronic inflammation, fibrosis, and even cirrhosis and liver failure. In this review, we focus on the role of bile acids in the inflammatory aspects of autoimmune liver diseases.<\/jats:p>","DOI":"10.3390\/cells12232725","type":"journal-article","created":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T03:48:24Z","timestamp":1701229704000},"page":"2725","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Bile Acids in Autoimmune Liver Disease: Unveiling the Nexus of Inflammation, Inflammatory Cells, and Treatment Strategies"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5722-6954","authenticated-orcid":false,"given":"Tianhao","family":"Zhou","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"AbdiGhani","family":"Ismail","sequence":"additional","affiliation":[{"name":"Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Francis","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA"},{"name":"Department of Research, Richard L. Roudebush VA Medical Center, Indianapolis, IN 46202, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"939","DOI":"10.3389\/fphar.2018.00939","article-title":"Bile Acid Synthesis: From Nature to the Chemical Modification and Synthesis and Their Applications as Drugs and Nutrients","volume":"9","author":"Mikov","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"108457","DOI":"10.1016\/j.pharmthera.2023.108457","article-title":"Bile acid metabolism and signaling: Emerging pharmacological targets of dietary polyphenols","volume":"248","author":"Tveter","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"829525","DOI":"10.3389\/fimmu.2022.829525","article-title":"The Emerging Role of Bile Acids in the Pathogenesis of Inflammatory Bowel Disease","volume":"13","author":"Thomas","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00281-021-00869-6","article-title":"Role of bile acids in inflammatory liver diseases","volume":"43","author":"Evangelakos","year":"2021","journal-title":"Semin. Immunopathol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.livres.2017.05.001","article-title":"Bile acid metabolism and signaling in liver disease and therapy","volume":"1","author":"Chiang","year":"2017","journal-title":"Liver Res."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Zeng, J., Fan, J., and Zhou, H. (2023). Bile acid-mediated signaling in cholestatic liver diseases. Cell Biosci., 13.","DOI":"10.1186\/s13578-023-01035-1"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/s41579-022-00805-x","article-title":"Bile acids and the gut microbiota: Metabolic interactions and impacts on disease","volume":"21","author":"Collins","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1053\/j.gastro.2023.02.022","article-title":"The Gut Microbial Bile Acid Modulation and Its Relevance to Digestive Health and Diseases","volume":"164","author":"Fogelson","year":"2023","journal-title":"Gastroenterology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"101210","DOI":"10.1016\/j.plipres.2022.101210","article-title":"Bile acids and their receptors in regulation of gut health and diseases","volume":"89","author":"Lin","year":"2023","journal-title":"Prog. Lipid Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1146\/annurev.biochem.72.121801.161712","article-title":"The enzymes, regulation, and genetics of bile acid synthesis","volume":"72","author":"Russell","year":"2003","journal-title":"Annu. Rev. Biochem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1194\/jlr.R800026-JLR200","article-title":"Fifty years of advances in bile acid synthesis and metabolism","volume":"50","author":"Russell","year":"2009","journal-title":"J. Lipid Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cmet.2016.05.005","article-title":"Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism","volume":"24","author":"Sayin","year":"2016","journal-title":"Cell Metab."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Xue, R., Su, L., Lai, S., Wang, Y., Zhao, D., Fan, J., Chen, W., Hylemon, P.B., and Zhou, H. (2021). Bile Acid Receptors and the Gut-Liver Axis in Nonalcoholic Fatty Liver Disease. Cells, 10.","DOI":"10.3390\/cells10112806"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1002\/hep.32568","article-title":"Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD","volume":"76","author":"Smirnova","year":"2022","journal-title":"Hepatology"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Yang, G., Jena, P.K., Hu, Y., Sheng, L., Chen, S.Y., Slupsky, C.M., Davis, R., Tepper, C.G., and Wan, Y.Y. (2023). The essential roles of FXR in diet and age influenced metabolic changes and liver disease development: A multi-omics study. Biomark. Res., 11.","DOI":"10.1186\/s40364-023-00458-9"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Yang, G., Liu, R., Rezaei, S., Liu, X., and Wan, Y.Y. (2023). Uncovering the Gut-Liver Axis Biomarkers for Predicting Metabolic Burden in Mice. Nutrients, 15.","DOI":"10.3390\/nu15153406"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41395-018-0390-3","article-title":"Diagnosis and Management of Primary Biliary Cholangitis","volume":"114","author":"Younossi","year":"2019","journal-title":"Am. J. Gastroenterol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Hitomi, Y., and Nakamura, M. (2023). The Genetics of Primary Biliary Cholangitis: A GWAS and Post-GWAS Update. Genes, 14.","DOI":"10.3390\/genes14020405"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3904\/kjim.2019.234","article-title":"Environmental risk factors and comorbidities of primary biliary cholangitis in Korea: A case-control study","volume":"36","author":"Kim","year":"2021","journal-title":"Korean J. Intern. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1177\/1535370217748893","article-title":"Environmental basis of primary biliary cholangitis","volume":"243","author":"Tanaka","year":"2018","journal-title":"Exp. Biol. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"170","DOI":"10.32074\/1591-951X-245","article-title":"Autoimmune biliary diseases: Primary biliary cholangitis and primary sclerosing cholangitis","volume":"113","author":"Sarcognato","year":"2021","journal-title":"Pathologica"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.bpg.2018.06.006","article-title":"Risk stratification and prognostic modelling in primary biliary cholangitis","volume":"34\u201335","author":"Goet","year":"2018","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/hep.30174","article-title":"Primary Biliary Cholangitis in Medicare Population: The Impact on Mortality and Resource Use","volume":"69","author":"Sayiner","year":"2019","journal-title":"Hepatology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"109680","DOI":"10.1016\/j.mehy.2020.109680","article-title":"Canal of Hering loss is an initiating step for primary biliary cholangitis (PBC): A hypothesis","volume":"140","author":"Theise","year":"2020","journal-title":"Med. Hypotheses"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jhep.2022.07.034","article-title":"Secretin alleviates biliary and liver injury during late-stage primary biliary cholangitis via restoration of secretory processes","volume":"78","author":"Kennedy","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jaut.2016.08.006","article-title":"Hydrophobic bile acids suppress expression of AE2 in biliary epithelial cells and induce bile duct inflammation in primary biliary cholangitis","volume":"75","author":"Hisamoto","year":"2016","journal-title":"J. Autoimmun."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/MOG.0000000000000525","article-title":"Obeticholic acid in primary biliary cholangitis: Where we stand","volume":"35","author":"Manne","year":"2019","journal-title":"Curr. Opin. Gastroenterol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/hep.30479","article-title":"Factors Associated With Outcomes of Patients With Primary Sclerosing Cholangitis and Development and Validation of a Risk Scoring System","volume":"69","author":"Goode","year":"2019","journal-title":"Hepatology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41575-019-0125-y","article-title":"Cholangiocyte pathobiology","volume":"16","author":"Banales","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.3748\/wjg.v26.i21.2768","article-title":"Gut microbiome in primary sclerosing cholangitis: A review","volume":"26","author":"Little","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.30662","article-title":"Cholangiocyte-Derived Exosomal Long Noncoding RNA H19 Promotes Hepatic Stellate Cell Activation and Cholestatic Liver Fibrosis","volume":"70","author":"Liu","year":"2019","journal-title":"Hepatology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"29","DOI":"10.21037\/tgh-20-266","article-title":"Primary sclerosing cholangitis","volume":"6","author":"Rabiee","year":"2021","journal-title":"Transl. Gastroenterol. Hepatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"531","DOI":"10.14218\/JCTH.2021.00344","article-title":"Primary Sclerosing Cholangitis and Inflammatory Bowel Disease: A Review","volume":"10","author":"Vaziri","year":"2022","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"9437043","DOI":"10.1155\/2019\/9437043","article-title":"Autoimmune Hepatitis-Immunologically Triggered Liver Pathogenesis-Diagnostic and Therapeutic Strategies","volume":"2019","author":"Sucher","year":"2019","journal-title":"J. Immunol. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.dld.2019.01.015","article-title":"Incidence, prevalence, and causes of death of patients with autoimmune hepatitis: A nationwide register-based cohort study in Finland","volume":"51","author":"Puustinen","year":"2019","journal-title":"Dig. Liver Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/liv.13458","article-title":"Autoimmune hepatitis: From current knowledge and clinical practice to future research agenda","volume":"38","author":"Sebode","year":"2018","journal-title":"Liver Int."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.cgh.2013.08.039","article-title":"Cholestatic phenotypes of autoimmune hepatitis","volume":"12","author":"Czaja","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Cheng, Z., Yang, L., and Chu, H. (2022). The Gut Microbiota: A Novel Player in Autoimmune Hepatitis. Front. Cell Infect. Microbiol., 12.","DOI":"10.3389\/fcimb.2022.947382"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"\u00d6zdirik, B., M\u00fcller, T., Wree, A., Tacke, F., and Sigal, M. (2021). The Role of Microbiota in Primary Sclerosing Cholangitis and Related Biliary Malignancies. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22136975"},{"key":"ref_40","first-page":"958","article-title":"Targeting Gut Microbiota for the Treatment of Primary Biliary Cholangitis: From Bench to Bedside","volume":"11","author":"Zhang","year":"2023","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/cphy.c120019","article-title":"Physiology of cholangiocytes","volume":"3","author":"Tabibian","year":"2013","journal-title":"Compr. Physiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1111\/liv.13880","article-title":"Novel and emerging therapies for cholestatic liver diseases","volume":"38","author":"Goldstein","year":"2018","journal-title":"Liver Int."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"G60","DOI":"10.1152\/ajpgi.00112.2022","article-title":"Loss of apical sodium bile acid transporter alters bile acid circulation and reduces biliary damage in cholangitis","volume":"324","author":"Meadows","year":"2023","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/hep.29804","article-title":"Bile acids stimulate cholangiocyte fluid secretion by activation of transmembrane member 16A Cl(-) channels","volume":"68","author":"Li","year":"2018","journal-title":"Hepatology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3748\/wjg.v29.i2.357","article-title":"Secondary bile acids and the biliary epithelia: The good and the bad","volume":"29","author":"Lenci","year":"2023","journal-title":"World J. Gastroenterol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Duan, S., Li, X., Fan, G., and Liu, R. (2022). Targeting bile acid signaling for the treatment of liver diseases: From bench to bed. Biomed. Pharmacother., 152.","DOI":"10.1016\/j.biopha.2022.113154"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/hep.29076","article-title":"The role of sphingosine 1-phosphate receptor 2 in bile-acid-induced cholangiocyte proliferation and cholestasis-induced liver injury in mice","volume":"65","author":"Wang","year":"2017","journal-title":"Hepatology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1002\/hep.30698","article-title":"Long Noncoding RNA H19 Contributes to Cholangiocyte Proliferation and Cholestatic Liver Fibrosis in Biliary Atresia","volume":"70","author":"Xiao","year":"2019","journal-title":"Hepatology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"949033","DOI":"10.3389\/fimmu.2022.949033","article-title":"Bile acids in immunity: Bidirectional mediators between the host and the microbiota","volume":"13","author":"Godlewska","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"101094","DOI":"10.1016\/j.plipres.2021.101094","article-title":"Bile acids and their receptors in metabolic disorders","volume":"82","author":"Fiorucci","year":"2021","journal-title":"Prog. Lipid Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1053\/j.gastro.2004.08.001","article-title":"The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis","volume":"127","author":"Fiorucci","year":"2004","journal-title":"Gastroenterology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/164_2019_236","article-title":"Bile Acid-Activated Receptors: A Review on FXR and Other Nuclear Receptors","volume":"256","author":"Shin","year":"2019","journal-title":"Handb. Exp. Pharmacol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"6657","DOI":"10.4049\/jimmunol.0901347","article-title":"The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis","volume":"183","author":"Mencarelli","year":"2009","journal-title":"J. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.bbadis.2015.11.001","article-title":"Splenic dendritic cell involvement in FXR-mediated amelioration of DSS colitis","volume":"1862","author":"Massafra","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1002\/hep.32028","article-title":"Mast Cells Regulate Ductular Reaction and Intestinal Inflammation in Cholestasis Through Farnesoid X Receptor Signaling","volume":"74","author":"Meadows","year":"2021","journal-title":"Hepatology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"718","DOI":"10.4049\/jimmunol.1700183","article-title":"The Bile Acid Receptor GPBAR1 Regulates the M1\/M2 Phenotype of Intestinal Macrophages and Activation of GPBAR1 Rescues Mice from Murine Colitis","volume":"199","author":"Biagioli","year":"2017","journal-title":"J. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"609060","DOI":"10.3389\/fimmu.2020.609060","article-title":"TGR5 Regulates Macrophage Inflammation in Nonalcoholic Steatohepatitis by Modulating NLRP3 Inflammasome Activation","volume":"11","author":"Shi","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/hep.21458","article-title":"The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells","volume":"45","author":"Keitel","year":"2007","journal-title":"Hepatology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1365-2567.2012.03554.x","article-title":"Bile acids induce monocyte differentiation toward interleukin-12 hypo-producing dendritic cells via a TGR5-dependent pathway","volume":"136","author":"Ichikawa","year":"2012","journal-title":"Immunology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jcmgh.2019.06.003","article-title":"GPBAR1 Functions as Gatekeeper for Liver NKT Cells and provides Counterregulatory Signals in Mouse Models of Immune-Mediated Hepatitis","volume":"8","author":"Biagioli","year":"2019","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Zhou, X., Guan, Z., Jin, X., Zhao, J., Chen, G., Ding, J., Ren, Y., Zhai, X., Zhou, Q., and Guan, Z. (2021). Reversal of alopecia areata, osteoporosis follow treatment with activation of Tgr5 in mice. Biosci. Rep., 41.","DOI":"10.1042\/BSR20210609"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.3389\/fimmu.2018.01853","article-title":"Bile Acids Activated Receptors Regulate Innate Immunity","volume":"9","author":"Fiorucci","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41586-020-2193-0","article-title":"Bacterial metabolism of bile acids promotes generation of peripheral regulatory T cells","volume":"581","author":"Campbell","year":"2020","journal-title":"Nature"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41586-019-1865-0","article-title":"Microbial bile acid metabolites modulate gut ROR\u03b3(+) regulatory T cell homeostasis","volume":"577","author":"Song","year":"2020","journal-title":"Nature"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.jhep.2019.05.030","article-title":"Liver infiltrating T cells regulate bile acid metabolism in experimental cholangitis","volume":"71","author":"Glaser","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/cld.861","article-title":"Bile Acid Biology, Pathophysiology, and Therapeutics","volume":"15","author":"Chiang","year":"2020","journal-title":"Clin. Liver Dis."},{"key":"ref_67","first-page":"101133","article-title":"A multi-society Delphi consensus statement on new fatty liver disease nomenclature","volume":"29","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jhep.2020.02.033","article-title":"A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis","volume":"73","author":"Kowdley","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/hep.30509","article-title":"The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis","volume":"70","author":"Trauner","year":"2019","journal-title":"Hepatology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/hep.32599","article-title":"IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH","volume":"77","author":"Xu","year":"2023","journal-title":"Hepatology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/j.dld.2019.12.129","article-title":"Tropifexor, a highly potent FXR agonist, produces robust and dose-dependent reductions in hepatic fat and serum alanine aminotransferase in patients with fibrotic NASH after 12 weeks of therapy: FLIGHT-FXR Part C interim results","volume":"52","author":"Lucas","year":"2020","journal-title":"Dig. Liver Dis."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/hep4.1209","article-title":"NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial","volume":"2","author":"Mayo","year":"2018","journal-title":"Hepatol. Commun."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S2468-1253(22)00017-6","article-title":"Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2\/3): A randomised, double-blind, placebo-controlled, phase 2b trial","volume":"7","author":"Harrison","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jhep.2018.10.035","article-title":"Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial","volume":"70","author":"Hirschfield","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/S0140-6736(17)30319-7","article-title":"Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: A double-blind, randomised, placebo-controlled, crossover, phase 2a study","volume":"389","author":"Hegade","year":"2017","journal-title":"Lancet"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/j.cgh.2022.10.032","article-title":"GLIMMER: A Randomized Phase 2b Dose-Ranging Trial of Linerixibat in Primary Biliary Cholangitis Patients With Pruritus","volume":"21","author":"Levy","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1038\/s41598-018-25214-0","article-title":"Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis","volume":"8","author":"Wahlin","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/hep4.1305","article-title":"A Randomized, Controlled, Phase 2 Study of Maralixibat in the Treatment of Itching Associated With Primary Biliary Cholangitis","volume":"3","author":"Mayo","year":"2019","journal-title":"Hepatol. Commun."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e0153","DOI":"10.1097\/HC9.0000000000000153","article-title":"Safety, tolerability, and efficacy of maralixibat in adults with primary sclerosing cholangitis: Open-label pilot study","volume":"7","author":"Bowlus","year":"2023","journal-title":"Hepatol. Commun."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jhep.2020.07.028","article-title":"Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis","volume":"74","author":"Frisch","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/hep.29569","article-title":"A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis","volume":"67","author":"Kowdley","year":"2018","journal-title":"Hepatology"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jhep.2016.12.005","article-title":"The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction","volume":"66","author":"Schwabl","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"9960","DOI":"10.1021\/acs.jmedchem.7b00907","article-title":"Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)","volume":"60","author":"Tully","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Cipriani, S., Renga, B., D\u2019Amore, C., Simonetti, M., De Tursi, A.A., Carino, A., Monti, M.C., Sepe, V., Zampella, A., and Fiorucci, S. (2015). Impaired Itching Perception in Murine Models of Cholestasis Is Supported by Dysregulation of GPBAR1 Signaling. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0129866"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"100255","DOI":"10.1016\/j.jhepr.2021.100255","article-title":"Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases","volume":"3","author":"Sanyal","year":"2021","journal-title":"JHEP Rep."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/23\/2725\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:33:06Z","timestamp":1760131986000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/23\/2725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,29]]},"references-count":85,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["cells12232725"],"URL":"https:\/\/doi.org\/10.3390\/cells12232725","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,29]]}}}